Zhang Jie, Fang Qingyun, Huang Yiyu, Qu Yilun, Liu Qun, Li Run, Zhou Yena, Cui Shaoyuan, Liu Ran, Wang Xu, Bai Yunfeng, Duan Shuwei, Wu Lingling, Chen Pu, Wang Yong, Wu Jie, Sun Xuefeng, Cai Guangyan, Zheng Ying, Hong Quan, Chen Xiangmei
School of Medicine, Nankai University, Tianjin 300071, China.
Department of Nephrology, First Medical Center of Chinese PLA General Hospital, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Medical Devices and Integrated Traditional Chinese and Western Drug Development for Severe Kidney Diseases, Beijing Key Laboratory of Digital Intelligent TCM for the Prevention and Treatment of Pan-vascular Diseases, Key Disciplines of National Administration of Traditional Chinese Medicine(zyyzdxk-2023310), Beijing 100853, China.
Research (Wash D C). 2025 Jun 2;8:0716. doi: 10.34133/research.0716. eCollection 2025.
Mesangial proliferative glomerulonephritis (MsPGN) is the most common glomerulonephritis pathological type, including IgA nephropathy (IgAN), in which regional immune injury leads to disease progression without targeted treatment approaches. The mechanism of regional immune injury in MsPGN is unclear. We previously performed single-cell RNA sequencing (scRNA-seq) of IgAN and identified that the gene increased in kidney. In this study, further scRNA-seq analysis and cellchat analysis revealed that and expression was increased in mesangial cells and monocytes/macrophages, respectively, in IgAN, mediating stronger crosstalk. This result and its association with regional immune injury were validated in clinical specimens and MsPGN animal model. Deficiency of monocytes/macrophages in the MsPGN animal model attenuated proteinuria, cell proliferation, and inflammation in glomerulus. Mechanistically, CX3CL1 in activated mesangial cells induced monocyte/macrophage migration and activation, and RNA-seq, Luminex multiplex immunoassay, and molecular analysis revealed that monocytes/macrophages induced mesangial cell injury via the MIF-CD74 interaction and activated the phosphatidylinositol 3-kinase (PI3K)/proteinserine-threonine kinase (AKT) pathway. Lastly, the therapeutic effect of the CX3CL1 monoclonal antibody quetmolimab was validated for inhibiting the progression of MsPGN. These findings demonstrate that activated mesangial cells interact with monocytes/macrophages promoting glomerulus regional immune injury in MsPGN, providing evidence into the CX3CL1-CX3CR1 axis as a novel target of treatment for MsPGN.
系膜增生性肾小球肾炎(MsPGN)是最常见的肾小球肾炎病理类型,包括IgA肾病(IgAN),其中局部免疫损伤导致疾病进展且缺乏针对性治疗方法。MsPGN中局部免疫损伤的机制尚不清楚。我们之前对IgAN进行了单细胞RNA测序(scRNA-seq),并确定了在肾脏中增加的基因。在本研究中,进一步的scRNA-seq分析和CellChat分析显示,在IgAN中,系膜细胞和单核细胞/巨噬细胞中分别增加了和的表达,介导了更强的细胞间通讯。这一结果及其与局部免疫损伤的关联在临床标本和MsPGN动物模型中得到了验证。MsPGN动物模型中单核细胞/巨噬细胞的缺乏减轻了蛋白尿、细胞增殖和肾小球炎症。机制上,活化的系膜细胞中的CX3CL1诱导单核细胞/巨噬细胞迁移和活化,RNA测序、Luminex多重免疫测定和分子分析显示,单核细胞/巨噬细胞通过MIF-CD74相互作用诱导系膜细胞损伤并激活磷脂酰肌醇3激酶(PI3K)/蛋白丝氨酸苏氨酸激酶(AKT)途径。最后,验证了CX3CL1单克隆抗体quetmolimab抑制MsPGN进展的治疗效果。这些发现表明,活化的系膜细胞与单核细胞/巨噬细胞相互作用,促进MsPGN中的肾小球局部免疫损伤,为CX3CL1-CX3CR1轴作为MsPGN的新治疗靶点提供了证据。